The Cannabis Strain Naming Problem: Why “Blue Dream” Means Different Things Everywhere

Walk into a dispensary in California and buy an eighth of Blue Dream. Then fly to Colorado and buy Blue Dream there. Then try it in Michigan. Chances are you will have three noticeably different experiences — different appearance, different aroma, different effects — despite paying for what the labels claim is the same strain.

This is the cannabis strain naming problem, and it is one of the industry’s most persistent and underaddressed consumer issues. In a market that prides itself on variety and invests enormous energy in strain culture, the fundamental unit of that culture — the strain name — is remarkably unreliable.

How We Got Here

The strain naming problem has roots in cannabis’s decades in the illicit market, where there was no regulatory body, no naming authority, and no genetic verification. Growers created crosses, gave them names, and those names spread through word of mouth, seed trades, and clone sharing. Along the way, names got misapplied, genetics drifted, and the connection between a name and a specific genetic profile became increasingly tenuous.

Several factors contributed to the current chaos:

Phenotypic variation: Even within a single strain, different phenotypes (physical expressions of the same genetics) can produce dramatically different plants. Two growers starting with authentic OG Kush seeds might end up with plants that look, smell, and smoke quite differently depending on which phenotype each selected and stabilized.

Unverified clones: The traditional method of preserving a strain — sharing clones — relies on a chain of custody that was never documented. A clone passed through five growers might be relabeled at any point, either intentionally or through honest mix-up. By the time it reaches a dispensary, there is no way to verify it matches the original genetics.

Intentional renaming: Some growers rename existing strains to create perceived novelty or to distance a product from negative associations. A mediocre harvest of a well-known strain might be renamed to avoid comparison, while a good harvest of an unknown strain might be given a famous name to boost sales.

Seed company proliferation: Dozens of seed companies now sell “Blue Dream” seeds, each produced from their own breeding stock. Without a centralized registry or genetic standard defining what Blue Dream actually is at the DNA level, all of these versions are equally “legitimate” — and equally different from each other.

What the Research Shows

Genetic studies have confirmed what experienced consumers have suspected for years. A landmark 2023 study published in PLOS ONE analyzed 122 cannabis samples from dispensaries across six states, all labeled with one of nine common strain names. The findings were striking:

• Samples sharing the same strain name were no more genetically similar to each other than samples with completely different names
• Some samples labeled as distinct strains were genetically identical
• The indica/sativa classification on labels showed no consistent correlation with the plants’ actual genetic lineage

A follow-up study in 2025 expanded the analysis to over 300 samples and reached the same conclusions. The researchers described the current strain naming system as “essentially arbitrary” from a genetic standpoint.

This does not mean that all cannabis is the same — far from it. There are genuine and significant chemical differences between cannabis varieties. The problem is that strain names do not reliably predict those differences. Two plants called “Gorilla Glue” may have completely different cannabinoid and terpene profiles, while two plants with different names may be chemically near-identical.

Why It Matters for Consumers

The strain naming problem is not just an academic curiosity. It has real consequences for consumers:

Medical patients who find relief from a specific strain may be unable to replicate that experience at a different dispensary, even when purchasing the same name. For patients using cannabis to manage migraines or other conditions where consistent dosing matters, this variability is a genuine clinical problem.

Consumer trust erodes when people pay premium prices for a specific strain and receive something that does not match their expectations. In any other consumer product category, this level of naming inconsistency would be considered mislabeling.

Purchasing decisions are impaired when the primary way consumers navigate product selection — strain names — does not reliably predict the experience. Browsing a dispensary’s strain menu becomes more like a lottery than an informed choice.

What Is Being Done

Several initiatives are working to address the naming problem:

Genetic Testing and Certification

Companies specializing in cannabis genetic testing now offer services that can verify whether a sample matches a defined genetic profile. Some dispensaries and cultivators are beginning to include genetic verification alongside standard potency and contaminant testing.

The challenge is establishing reference standards — someone has to decide what the “real” Blue Dream genome looks like, and getting industry consensus on reference genetics is politically and commercially complicated. Our strain database attempts to document strain lineages and expected profiles, but genetic verification remains the missing piece.

Chemotype-Based Classification

A growing movement advocates replacing strain names with chemotype profiles as the primary way consumers select cannabis. Under this approach, products would be marketed primarily by their cannabinoid ratios, dominant terpenes, and expected effects rather than by strain name.

Some dispensaries have already adopted effect-based categorization on their menus — grouping products by “relaxing,” “energizing,” “creative,” and so on rather than by strain name. While imperfect, this approach at least directs consumers toward products likely to produce their desired experience.

Standardized Cultivar Registration

The International Cannabis Farmers Association and similar organizations are developing frameworks for cultivar registration that would function similarly to plant patent systems in traditional agriculture. Under such a system, a strain name would be legally tied to a specific genetic profile, and using that name without verified genetics would constitute trademark infringement.

Progress has been slow, in part because federal illegality prevents cannabis varieties from being registered through the US Patent and Trademark Office’s standard plant variety protections.

What Consumers Can Do Now

Until the industry solves the naming problem systemically, consumers can take several steps to make more informed purchases:

Focus on lab results, not names: Look at the THC/CBD percentages, terpene profiles, and any other chemical data provided. These tell you more about what a product will do than the strain name does.

Develop terpene literacy: Learning to identify and seek out specific terpenes — myrcene for relaxation, limonene for mood elevation, pinene for alertness — gives you a vocabulary for describing what you want that is more useful than strain names. Our strain guides emphasize terpene profiles for this reason.

Build relationships with specific cultivators: If you find flower from a specific grower that you enjoy, seek out that cultivator’s products regardless of strain name. Consistency in growing practices often matters more than genetics for the end consumer experience.

Use your senses: Before purchasing, examine the flower if possible. Smell it. Look at the trichome coverage, the color, the structure. Your senses can tell you more about quality and likely effects than any name on a label.

The Future of Strain Identity

The cannabis strain naming problem will not be resolved quickly, but the trajectory is toward greater standardization and transparency. As genetic testing becomes cheaper and more widespread, as chemotype-based marketing gains traction, and as regulatory frameworks mature, the gap between what a strain name promises and what the product delivers will narrow.

In the meantime, the most sophisticated cannabis consumers are already moving beyond strain name loyalty and toward a more holistic assessment of what they are buying. The strain name may never become irrelevant — brand names rarely do in consumer markets — but its role is shifting from sole identifier to one data point among many.